On Sept. 29, 2020, Windtree Therapeutics announced that FDA had accepted its Investigational New Drug application for a Phase 2 clinical trial studying lyo lucinactant, its KL4 surfactant drug, in COVID-19 associated lung injury and acute respiratory distress syndrome (ARDS) patients.

Lucinactant is also used in the Company’s drug and device combination development program called AEROSURFﾮ, being developed for treating preterm infants with Respiratory Distressed Syndromes.